
|Articles|February 1, 2005
Iris pigmentation changes monitored with glaucoma therapy
Uppsala, Sweden—Adjunctive latanoprost (Xalatan, Pfizer) therapy for open-angle glaucoma is safe and effective, based on the results of a 5-year assessment of the drug. The mean decrease in IOP was 25% of the baseline IOP and this was sustained without any treatment change in 70% of eyes.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
AAO 2025: Glaucoma laser surgery with Joel S. Schuman, MD, FACS
2
AAO 2025: Philip J. Ferrone, MD, highlights safety and efficacy findings of gildeuretinol in Stargardt disease
3
News from Orlando: AAO 2025 highlights research across all areas of eyecare
4
AAO 2025: Clinical outcomes of early vs delayed pegcetacoplan treatment in GA
5


















































.png)


